 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | HLX301 / Fosun Pharma
Trial primary completion date, Metastases: A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT (clinicaltrials.gov) - Aug 8, 2023
P1/2, N=30, Recruiting, Sponsor: Shanghai Henlius Biotech
Trial primary completion date: Jun 2023 --> Sep 2023
- || HLX301 / Fosun Pharma
Trial primary completion date, IO biomarker, Metastases: HLX301 (TIGIT (clinicaltrials.gov) - Aug 8, 2023
P1/2, N=150, Recruiting, Sponsor: Shanghai Henlius Biotech
Trial primary completion date: Jun 2023 --> Sep 2023 Trial primary completion date: Mar 2023 --> Sep 2023
- || HLX301 / Fosun Pharma
Enrollment open, Metastases: A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT (clinicaltrials.gov) - Jul 13, 2022
P1/2, N=30, Recruiting, Sponsor: Shanghai Henlius Biotech
Trial primary completion date: Mar 2023 --> Sep 2023 Not yet recruiting --> Recruiting
- || HLX301 / Fosun Pharma
New P1/2 trial, Metastases: A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT (clinicaltrials.gov) - May 24, 2022
P1/2, N=30, Not yet recruiting, Sponsor: Shanghai Henlius Biotech
- || HLX301 / Fosun Pharma
Trial initiation date, IO biomarker, Metastases: HLX301 (TIGIT (clinicaltrials.gov) - Apr 26, 2022
P1/2, N=150, Recruiting, Sponsor: Shanghai Henlius Biotech
Not yet recruiting --> Recruiting Initiation date: Jan 2022 --> May 2022
- ||| HLX301 / Fosun Pharma
Enrollment open, IO biomarker, Metastases: HLX301 (TIGIT (clinicaltrials.gov) - Jan 11, 2022
P1/2, N=150, Recruiting, Sponsor: Shanghai Henlius Biotech
Initiation date: Jan 2022 --> May 2022 Not yet recruiting --> Recruiting
- |||| HLX301 / Fosun Pharma
New P1/2 trial, IO biomarker, Metastases: HLX301 (TIGIT (clinicaltrials.gov) - Oct 31, 2021
P1/2, N=150, Not yet recruiting, Sponsor: Shanghai Henlius Biotech